Ripertamab Biosimilar Monoclonal Antibody (CD20) for Research

Cat No.: GMP-Bios-ab-485

Pre-Made Ripertamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-485-1mg 1mg 3090

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Ripertamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
INN Name Ripertamab
TargetCD20
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure2osl:HL:AB/6y90:HL:CD/6vja:HL:IM
99% SI Structure4kaq:HL
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesSinocelltech
Conditions Approvedna
Conditions ActiveNon-Hodgkin's lymphoma
Conditions Discontinuedna
Development Techna



About target - MS4A1

1. Protein B-lymphocyte antigen CD20

2. Gene MS4A1

3. Organism Homo sapiens (Human)

Function

B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111).

Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:7684739, PubMed:12920111, PubMed:18474602).

Caution

Epitope 1, mapped in PubMed:16785532, is predicted to be buried in the membrane. Its accessibility to the extracellular space, and thus to antibody recognition, is not explained.